Eli Lilly and Company (NYSE:LLY) Shares Sold by CFS Investment Advisory Services LLC

CFS Investment Advisory Services LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 39.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,196 shares of the company’s stock after selling 2,734 shares during the quarter. CFS Investment Advisory Services LLC’s holdings in Eli Lilly and Company were worth $3,717,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Westwood Holdings Group Inc. boosted its stake in shares of Eli Lilly and Company by 5.4% during the first quarter. Westwood Holdings Group Inc. now owns 3,839 shares of the company’s stock worth $2,987,000 after buying an additional 196 shares during the period. Guardian Capital LP lifted its position in Eli Lilly and Company by 3.0% during the 1st quarter. Guardian Capital LP now owns 921 shares of the company’s stock worth $717,000 after acquiring an additional 27 shares during the period. Linscomb Wealth Inc. grew its stake in shares of Eli Lilly and Company by 0.5% in the 1st quarter. Linscomb Wealth Inc. now owns 3,389 shares of the company’s stock valued at $2,637,000 after purchasing an additional 17 shares during the last quarter. Steel Grove Capital Advisors LLC increased its holdings in shares of Eli Lilly and Company by 104.9% in the first quarter. Steel Grove Capital Advisors LLC now owns 795 shares of the company’s stock valued at $618,000 after purchasing an additional 407 shares during the period. Finally, Beck Capital Management LLC raised its stake in shares of Eli Lilly and Company by 1.9% during the first quarter. Beck Capital Management LLC now owns 8,824 shares of the company’s stock worth $6,865,000 after purchasing an additional 163 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on LLY shares. Bank of America dropped their price objective on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Citigroup boosted their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Finally, BMO Capital Markets lifted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,007.94.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $748.91 on Friday. The firm’s fifty day moving average price is $868.53 and its 200 day moving average price is $869.14. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The company has a market capitalization of $710.96 billion, a price-to-earnings ratio of 80.96, a price-to-earnings-growth ratio of 2.76 and a beta of 0.43. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.10 earnings per share. On average, research analysts forecast that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.69%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.